| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel B Maselli, Michael Camiller. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Advances in experimental medicine and biology. vol 1307. 2021-01-19. PMID:32077010. |
glp-1 stimulates insulin secretion from β cells in the islets of langerhans. |
2021-01-19 |
2023-08-13 |
human |
| Daniel B Maselli, Michael Camiller. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Advances in experimental medicine and biology. vol 1307. 2021-01-19. PMID:32077010. |
exendin-4 is a peptide agonist of the glp-1 receptor that promotes insulin secretion. |
2021-01-19 |
2023-08-13 |
human |
| Bradley Anderson, Paula Carlson, Marcello Laurenti, Adrian Vella, Michael Camilleri, Anshuman Desai, Kelly Feuerhak, Adil E Bharuch. Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 32. issue 1. 2021-01-15. PMID:31691451. |
nutrient-mediated release of cholecystokinin and glucagon-like peptide-1 (glp-1) regulates gastric emptying (ge) via duodenogastric feedback mechanisms; glp-1 also regulates postprandial insulin secretion. |
2021-01-15 |
2023-08-13 |
Not clear |
| Alexander S Christensen, Sofie Hædersdal, Heidi Storgaard, Kathrine Rose, Nina L Hansen, Jens J Holst, Torben Hansen, Filip K Knop, Tina Vilsbøl. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers. Diabetes. vol 69. issue 9. 2021-01-15. PMID:32518064. |
gip and glp-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1α mutation carriers. |
2021-01-15 |
2023-08-13 |
Not clear |
| Alexander S Christensen, Sofie Hædersdal, Heidi Storgaard, Kathrine Rose, Nina L Hansen, Jens J Holst, Torben Hansen, Filip K Knop, Tina Vilsbøl. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers. Diabetes. vol 69. issue 9. 2021-01-15. PMID:32518064. |
the effect of sus together with gip or glp-1, respectively, on insulin and glucagon secretion in patients with hnf1a diabetes is currently unknown. |
2021-01-15 |
2023-08-13 |
Not clear |
| Alexandra M Bodnaruc, Denis Prud'homme, Isabelle Girou. Acute effects of an isocaloric macronutrient-matched breakfast meal containing almonds on glycemic, hormonal, and appetite responses in men with type 2 diabetes: a randomized crossover study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. vol 45. issue 5. 2021-01-13. PMID:31618605. |
blood samples were collected in fasting state as well as 15, 30, 60, 90, 120, and 240 min postprandially for quantifying blood glucose, as well as insulin and glucagon-like peptide-1 (glp-1) serum concentrations. |
2021-01-13 |
2023-08-13 |
human |
| Francesco Giorgino, Irene Caruso, Raffaele Napol. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes research and clinical practice. vol 170. 2021-01-11. PMID:33002548. |
a fixed-ratio combination of a glucagon-like peptide-1 receptor agonist (glp-1 ra) with basal insulin, such as lixisenatide with insulin glargine (iglarlixi), exploits the complementary mechanisms of action of each component to address hyperglycemia while mitigating potential adverse events (aes). |
2021-01-11 |
2023-08-13 |
Not clear |
| Francesco Giorgino, Irene Caruso, Raffaele Napol. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes research and clinical practice. vol 170. 2021-01-11. PMID:33002548. |
in the phase iii lixilan trials, iglarlixi resulted in significantly greater reductions in glycated hemoglobin (hba1c), better achievement of hba1c targets, less glycemic variability versus insulin glargine, lixisenatide or glp-1 ra alone, and was associated with weight control, less hypoglycemia versus insulin glargine, and fewer gi aes versus lixisenatide. |
2021-01-11 |
2023-08-13 |
Not clear |
| Mike Baxter, Yukiko Morimoto, Masami Tamiwa, Masakatsu Hattori, Xuejun Victor Peng, Robert Lubwama, Hiroshi Maegaw. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 11. issue 7. 2021-01-10. PMID:32445125. |
the effectiveness of basal insulin (bi) or glucagon-like peptide-1 receptor agonists (glp-1 ras) in providing glycemic control in patients with type 2 diabetes (t2d) in japanese routine practice is not well known. |
2021-01-10 |
2023-08-13 |
Not clear |
| Tsubasa Tani, Sho Nishikawa, Masaki Kato, Takanori Tsud. Delphinidin 3-rutinoside-rich blackcurrant extract ameliorates glucose tolerance by increasing the release of glucagon-like peptide-1 secretion. Food science & nutrition. vol 5. issue 4. 2021-01-09. PMID:28748082. |
pre-administered blackcurrant extract (bce) 5 mg/kg body weight (1 mg d3r/kg) significantly ameliorated glucose tolerance after intraperitoneal glucose injection in rats by stimulating the secretion of glp-1 and subsequently inducing insulin secretion. |
2021-01-09 |
2023-08-13 |
rat |
| Tiffany Rentsch, Magdi Awad, John M Moorman, Michael David Gothar. Evaluating the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Metabolic Changes in Patients With Type 2 Diabetes on High-Dose Insulin. American journal of therapeutics. vol Publish Ahead of Print. 2021-01-08. PMID:33416240. |
studies involving the glucagon-like peptide-1 receptor agonist (glp-1 ra) liraglutide have shown reductions in hemoglobin a1c (hba1c), weight, and insulin requirements in patients with type 2 diabetes mellitus (dm2) requiring high-dose insulin therapy. |
2021-01-08 |
2023-08-13 |
Not clear |
| Geisa Nogueira Salles, Michele Longoni Calió, Christian Hölscher, Cristina Pacheco-Soares, Marimelia Porcionatto, Anderson Oliveira Lob. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. Neuropharmacology. vol 162. 2021-01-06. PMID:31628935. |
the sister incretins glucagon-like peptide-1 (glp-1) and glucagon dependent insulinotropic polypeptide (gip) are growth factors responsible for re-sensitizing insulin signalling. |
2021-01-06 |
2023-08-13 |
human |
| Chioma Izzi-Engbeaya, Sophie Jones, Yoshibye Crustna, Pratibha C Machenahalli, Deborah Papadopoulou, Manish Modi, Christos Panayi, Jessica Starikova, Pei Chia Eng, Maria Phylactou, Edouard Mills, Lisa Yang, Risheka Ratnasabapathy, Mark Sykes, Isabella Plumptre, Ben Coumbe, Victoria C Wing, Ewa Pacuszka, Paul Bech, James Minnion, George Tharakan, Tricia Tan, Johannes Veldhuis, Ali Abbara, Alexander N Comninos, Waljit S Dhill. Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men. The Journal of clinical endocrinology and metabolism. vol 105. issue 4. 2021-01-04. PMID:32052032. |
glucagon-like peptide-1 (glp-1) potently reduces food intake and augments glucose-stimulated insulin secretion. |
2021-01-04 |
2023-08-13 |
Not clear |
| Pradeep Kumar Bhateja, Anu Kajal, Randhir Sing. Amelioration of Diabetes mellitus by modulation of GLP-1 via targeting alpha-glucosidase using Acacia tortilis polysaccharide in Streptozotocin-Nicotinamide induced diabetes in rats. Journal of Ayurveda and integrative medicine. vol 11. issue 4. 2021-01-01. PMID:33153880. |
polysaccharides decrease the glucose level by inhibiting α-glucosidase enzyme which further increases the level of glp-1 (glucagon-like peptide 1) to increase the insulin level as per earlier reports. |
2021-01-01 |
2023-08-13 |
rat |
| Marie Galmiche, Nicolas Lucas, Pierre Déchelotte, Camille Deroissart, Marie-Anne Le Solliec, Julie Rondeaux, Saida Azhar, Sébastien Grigioni, Guillaume Colange, Julie Delay, Najate Achamrah, Vanessa Folope, Liliana Belmonte, Adèle Lamarre, Agnès Rimbert, Tiphaine Saillard, André Petit, Muriel Quillard, Moise Coeffier, André Gillibert, Grégory Lambert, Romain Legrand, Marie-Pierre Tavolacc. Plasma Peptide Concentrations and Peptide-Reactive Immunoglobulins in Patients with Eating Disorders at Inclusion in the French EDILS Cohort (Eating Disorders Inventory and Longitudinal Survey). Nutrients. vol 12. issue 2. 2020-12-18. PMID:32085628. |
in 120 patients with restrictive (r), bulimic (b), and compulsive (c) ed, the plasma concentrations of leptin, glucagon-like peptide-1 (glp-1), peptide yy (pyy), and insulin were analyzed by milliplex and those of acyl ghrelin (ag), des-acyl ghrelin (dag), and α-melanocyte-stimulating hormone (α-msh) by elisa kits. |
2020-12-18 |
2023-08-13 |
Not clear |
| Marie Galmiche, Nicolas Lucas, Pierre Déchelotte, Camille Deroissart, Marie-Anne Le Solliec, Julie Rondeaux, Saida Azhar, Sébastien Grigioni, Guillaume Colange, Julie Delay, Najate Achamrah, Vanessa Folope, Liliana Belmonte, Adèle Lamarre, Agnès Rimbert, Tiphaine Saillard, André Petit, Muriel Quillard, Moise Coeffier, André Gillibert, Grégory Lambert, Romain Legrand, Marie-Pierre Tavolacc. Plasma Peptide Concentrations and Peptide-Reactive Immunoglobulins in Patients with Eating Disorders at Inclusion in the French EDILS Cohort (Eating Disorders Inventory and Longitudinal Survey). Nutrients. vol 12. issue 2. 2020-12-18. PMID:32085628. |
the concentrations of leptin, insulin, glp-1, and pyy were higher in c patients than in r patients. |
2020-12-18 |
2023-08-13 |
Not clear |
| Salinee Jantrapirom, Wutigri Nimlamool, Nipon Chattipakorn, Siriporn Chattipakorn, Piya Temviriyanukul, Woorawee Inthachat, Piyarat Govitrapong, Saranyapin Potikanon. Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity. International journal of molecular sciences. vol 21. issue 5. 2020-12-08. PMID:32138327. |
liraglutide, a glucagon-like peptide-1 (glp-1) analog and an antidiabetic agent, has a benefit in improving a peripheral insulin resistance. |
2020-12-08 |
2023-08-13 |
human |
| Rapeepun Chai-Udom, Suphab Aroonparkmongkol, Taninee Sahakitrungruan. Metabolic features and changes in glucose-induced serum glucagon-like peptide-1 levels in children with hypothalamic obesity. Journal of pediatric endocrinology & metabolism : JPEM. vol 33. issue 3. 2020-12-07. PMID:29389666. |
we assessed the metabolic syndrome features, fat mass, severity of hyperphagia using a standardized questionnaire, and measured glucose, insulin and glp-1 levels during a standard 75 g ogtt. |
2020-12-07 |
2023-08-13 |
human |
| Nasui Wang, Alvin W K Tan, Linda A Jahn, Lee Hartline, James T Patrie, Shaoda Lin, Eugene J Barrett, Kevin W Aylor, Zhenqi Li. Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance. Diabetes care. vol 43. issue 3. 2020-12-04. PMID:31888883. |
we aimed to examine whether glp-1 recruits microvasculature and improves the action of insulin in obese humans. |
2020-12-04 |
2023-08-13 |
Not clear |
| Kohei Kak. New concept of the glucagon-like peptide-1 signaling pathway on pancreatic insulin secretion. Journal of diabetes investigation. vol 11. issue 2. 2020-11-23. PMID:31472102. |
the intracellular glucagon-like peptide-1 (glp-1) signaling pathway, which involves cyclic adenosine monophosphate (camp), exchange protein directly activated by camp, camp-dependent protein kinase a (pka) and adenosine triphosphate-sensitive potassium channels, has been widely accepted as a common mechanism of glp-1-stimulated insulin secretion. |
2020-11-23 |
2023-08-13 |
Not clear |